
AUG 1 3 2007





PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

eduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

5 + 5

## **TRANSMITTAL FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/512,028
Filing Date	April 24, 2003
First Named Inventor	Jay WOHLGEMUTH
Art Unit	3700
Examiner Name	Not Yet Assigned
Attorney Docket Number	506612000103

ENCLOSURES (Check all that apply)					
LITOLOGOTEO (Check all that apply)					
Fee Transmittal Form	Drawing(s)		After Allowance Communication to TC		
Fee Attached	Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences		
Amendment/Reply .	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After Final	Petition to Convert to a Provisional Application		Proprietary Information		
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Ad	ddress	Status Letter		
Extension of Time Request	Terminal Disclaimer		X Other Enclosure(s) (please Identify below):		
Express Abandonment Request	Request for Refund  CD, Number of CD(s)		1. PTO/SB/08a/b (1 page)		
x Information Disclosure Statement (3 pages)			2. 5 References		
Certified Copy of Priority Document(s)	Landscape Table on C	CD	3. Return Receipt Postcard		
Reply to Missing Parts/ Incomplete Application	Remarks	te.			
Reply to Missing Parts under 37 CFR 1.52 or 1.53					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Name					
MORRISON & FOERSTER LLP (Customer No. 20872)					
Signature Of A					
Printed name Otis B. Littlefield					
Date August 13, 2007	F	Reg. No.	48,751		

I hereby certify that this paper is being deposited with th Commissioner for Patents, P.O. Box 1450, Alexandria, \				204US to MS Amendment,
Dated:August 13, 2007	Signature:	suessol	Colo	_ (Valerie Cohen)

I hereby certify that this paper is being deposited with the U.S. Postal Service via Express Mail Label No. EV513655204US to MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Dated: August 13, 2007 Signature: Value

Valoue Coho

Patent Docket No. 506612000103

AUG 1 3 2007 W

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

fir-re Patent Application of: Jay WOHLGEMUTH et al.

Serial No.: 10/512,028

Filing Date: April 24, 2003

For: METHODS AND COMPOSITIONS FOR

DIAGNOSING AND MONITORING AUTO IMMUNE AND CHRONIC INFLAMMATORY DISEASES Examiner: Not Yet Assigned

Group Art Unit: 3700

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

## Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

	This Supplemental Information Disclosure Statement is submitted:
	With the application; accordingly, no fee or separate requirements are required.
	Before the mailing of a first Office Action after the filing of a Request for Continued
	Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
	(e)(1) has been provided.
$\boxtimes$	Within three months of the application filing date or before mailing of a first Office
	Action on the merits; accordingly, no fee or separate requirements are required.
	However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
	After receipt of a first Office Action on the merits but before mailing of a final Office Action
	or Notice of Allowance.
	A fee is required. A check in the amount of is enclosed.
	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to
	this submission in duplicate.
	A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is
	believed to be due.
	After mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue fee.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
	amount of is enclosed.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
	form (PTO/SB/17 is attached to this submission in duplicate.)
	Applicants would appreciate the Examiner initialing and returning the Form

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplementa Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 506612000103.

Dated: August 13, 2007

Respectfully submitted,

Otis Littlefield

Registration No.: 48,751

MORRISON & FOERSTER LLP

425 Market Street

San Francisco, California 94105-2482

(415) 268-6846

ALTERNATIVE TO PTO/SB/08A/B (04/07) Complete if Known Application Number 10/512,028 **INFORMATION DISCLOSURE** Filing Date April 24, 2003 First Named Inventor Jay WOHLGEMUTH STATEMENT BY APPLICANT 3700 Art Unit (Use as many sheets as necessary) Examiner Name Not Yet Assigned Sheet 1 1 Attorney Docket Number 506612000103

	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					·

		FOREIC	SN PATENT I	DOCUMENTS	-	
Examiner Initials*	Cite No.¹	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
			•			

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1.	Alizadeh, A. A. et al. (2000). "Genomic-Scale Gene Expression Profiling of Normal and Malignant Immune Cells," <i>Current Opinion in Immunology</i> 12:219-225.	
	2.	Glynne, R. et al. (2000). "B-Lymphocyte Quiescence, Tolerance and Activation as Viewed by Global Gene Expression Profiling on Microarrays," <i>Immunological Reviews</i> 176:216-246.	
	3.	Glynne, R. J. et al. (2000). "Genomic-Scale Gene Expression Analysis of Lymphocyte Growth, Tolerance and Malignancy," <i>Current Opinion in Immunology</i> 12:210-214.	
	4.	Marrack, P. et al. (2000). "Genomic-Scale Analysis of Gene Expression in Resting and Activated T Cells," <i>Current Opinion in Immunology</i> 12:208-209.	
	5.	Supplemental Partial European Search Report mailed July 9, 2007, for EP Application No. 01997055.7 filed October 22, 2001, 6 pages.	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	<u> </u>
Examiner	Date
Signature	Considered
of 2270247	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.